Fulfilling the potential of DGKα inhibition for GBM and other cancers will likely require the development of new small-molecule inhibitors, but such work is underway and in the meantime there may be utility in a repurposed drug such as ritanserin. This evidence concerns the gene DGKA and glioblastoma.